D
Dorothee Nickles
Researcher at Genentech
Publications - 32
Citations - 7639
Dorothee Nickles is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & T cell. The author has an hindex of 17, co-authored 32 publications receiving 5113 citations. Previous affiliations of Dorothee Nickles include University of California, San Francisco & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Genetics of multiple sclerosis: swimming in an ocean of data.
TL;DR: A review of the major advances in the genetics of multiple sclerosis (MS) with a slight emphasis on data handling and analysis is provided in this paper, where a new genome-wide association study (GWAS) with almost 10, 000 cases (a collaboration between the Wellcome Trust and the international MS Genetics Consortium) identified new susceptibility loci, taking the total number of risk alleles to more than 50.
Journal ArticleDOI
The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease
Grant P Parnell,Prudence N. Gatt,Malgorzata Krupa,Dorothee Nickles,Fiona C. McKay,Stephen D. Schibeci,Marcel Batten,Sergio E. Baranzini,Andrew P.D. Henderson,Michael Barnett,Mark Slee,Steve Vucic,Graeme J. Stewart,David R. Booth +13 more
TL;DR: Optimal response to therapy might be indicated by normalization of expression of these genes in blood, after a marked over-representation of transcription factors controlling differentiation of T, B, myeloid and NK cells among the 110 MS genes now known to be associated with multiple sclerosis.
Journal ArticleDOI
Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
Fatema A. Legrand,David R. Gandara,Sanjeev Mariathasan,Thomas Powles,Xian He,Wei Zhang,Suchit Jhunjhunwala,Dorothee Nickles,Richard Bourgon,Erica B. Schleifman,Sarah M. Paul,Edward E. Kadel,Marcin Kowanetz,Craig Cummings,Yan Li,David Fabrizio,Eric Peters,Priti S. Hegde,Lukas C. Amler,David S. Shames +19 more
TL;DR: This data indicates that PD-L1 expression has limitations as a biomarker for checkpoint immunotherapy (CI) and suggests that prior atezolizumab monotherapy studies suggest improved efficacy in high tissue tumor mut...
Journal ArticleDOI
A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling
TL;DR: It is shown that caspase 4 is required for the induction of NF-κB activity, while it appears to be dispensable for the activation of the Jun N-terminal protein kinase signaling branch.
Journal ArticleDOI
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
Jonathan E. Rosenberg,Daniel P. Petrylak,Michiel S. van der Heijden,Andrea Necchi,Peter H. O'Donnell,Yohann Loriot,Margitta Retz,Jose Luis Perez-Gracia,Joaquim Bellmunt,Petros Grivas,Richard W. Joseph,Lawrence Fong,Edward E. Kadel,Zachary Boyd,Dorothee Nickles,Garrett M. Frampton,Richard Bourgon,Priti S. Hegde,Sanjeev Mariathasan,Thomas Powles +19 more
TL;DR: PD-L1 tumor-infiltrating immune cell (IC) status was associated with CD8+ T effector (Teff) gene expression levels, and response to atezo wasassociated with high expression of CXCL9.